MRMD · XBRL financial data

Marimed financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	50,895	—	—	—	—	—
Revenue from contracts with customers	50,895	121,464	134,010	148,598	157,964	159,826
Cost of revenue	19,570	55,201	70,053	82,679	95,096	101,945
Gross profit	31,325	66,263	63,957	65,919	62,868	57,881
General and administrative	9,899	27,561	20,735	22,132	25,618	26,142
Total operating expenses	16,794	39,400	43,588	51,534	59,956	60,701
Operating income (loss)	14,531	26,863	20,369	14,385	2,912	(2,820)
Interest expense	9,810	2,356	1,693	9,185	6,944	7,502
Other income (expense)	(85)	309	(127)	(1,635)	(50)	(717)
Income tax expense (benefit)	2,067	16,192	5,894	9,411	8,159	3,594
Net income (loss)	2,144	7,225	13,468	(16,031)	(12,164)	(14,484)
Earnings per share, basic USD per share	0.01	0.02	0.04	(0.04)	(0.03)	(0.04)
Earnings per share, diluted USD per share	0.01	0.02	0.04	(0.04)	(0.03)	(0.04)
Weighted average shares, basic thousands of shares	266,980	326,467	337,697	363,403	379,153	390,135
Weighted average shares, diluted thousands of shares	324,161	372,397	380,289	363,403	379,153	390,135

Fiscal years (MRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,999	29,683	9,737	14,645	7,282	8,884
Short-term investments	1,357	251	123	88	0	—
Accounts receivable	6,676	1,666	4,157	7,199	8,742	9,114
Inventory	6,831	9,768	19,477	25,306	33,488	36,601
Total current assets	21,043	44,613	44,146	51,432	53,509	59,290
Property and equipment, net	45,637	62,150	71,641	89,103	94,167	89,385
Right-of-use asset	5,247	5,081	4,931	9,716	8,730	7,723
Goodwill	2,068	2,068	8,079	11,993	15,812	24,002
Total assets	76,445	123,205	152,202	196,123	206,989	202,565
Accounts payable	5,045	5,099	6,626	9,001	13,189	14,586
Accrued liabilities	3,621	1,349	3,091	3,549	4,435	9,509
Total current liabilities	23,227	27,223	26,490	30,862	48,678	59,067
Lease liability, non-current	4,822	4,574	4,173	8,455	7,549	6,616
Total liabilities	53,620	49,181	57,167	107,209	128,113	137,831
Accumulated deficit	(104,617)	(97,392)	(83,924)	(99,955)	(112,119)	(127,932)
Total liabilities and equity	76,445	123,205	152,202	196,123	206,989	202,565
Common shares outstanding (cover page) thousands of shares	319,134	335,183	341,477	375,130	382,174	397,883

Fiscal years (MRMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	2,144	7,225	13,468	(16,031)	(12,164)	(14,484)
Stock-based compensation	—	—	6,338	1,020	1,050	1,860
Net cash from operating activities	3,380	35,855	7,311	7,910	6,785	7,695
Purchases of property and equipment	4,688	17,874	12,140	20,130	11,960	1,167
Net cash from investing activities	(4,463)	(16,624)	(26,244)	(25,985)	(17,133)	(1,380)
Net cash from financing activities	3,343	7,453	(1,013)	22,983	2,985	(4,713)
Net change in cash	2,260	26,684	(19,946)	4,908	(7,363)	1,602

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.